Trial Profile
A trial to study the early early experience on the feasibility and safety of 70-150 μm drug-eluting beads loaded with irinotecan (M1-DEBIRI) for treating unresectable hepatic colorectal metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2016
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 12 Jul 2016 New trial record
- 01 Jul 2016 Results published in the Anticancer Research